Editas Medicine (NASDAQ:EDIT) Upgraded at StockNews.com
StockNews.com upgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a sell rating to a hold rating in a research note published on Wednesday. Several other brokerages also recently issued reports on EDIT. Robert W. Baird lowered their price target on Editas Medicine from $8.00 to $4.00 and set an “outperform” rating for the […]
StockNews.com upgraded shares of Editas Medicine (NASDAQ:EDIT – Free Report) from a sell rating to a hold rating in a research note published on Wednesday. Several other brokerages also recently issued reports on EDIT. Robert W. Baird lowered their price target on Editas Medicine from $8.00 to $4.00 and set an “outperform” rating for the […]
